nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—PSMB10—hematopoietic system—thymus cancer	0.0449	0.0759	CbGeAlD
Carfilzomib—PSMB10—lymphoid tissue—thymus cancer	0.0316	0.0534	CbGeAlD
Carfilzomib—PSMB10—thyroid gland—thymus cancer	0.0287	0.0485	CbGeAlD
Carfilzomib—PSMB10—lung—thymus cancer	0.0261	0.0441	CbGeAlD
Carfilzomib—PSMB1—hematopoietic system—thymus cancer	0.0223	0.0377	CbGeAlD
Carfilzomib—PSMB2—hematopoietic system—thymus cancer	0.0218	0.0368	CbGeAlD
Carfilzomib—PSMB8—pituitary gland—thymus cancer	0.0215	0.0363	CbGeAlD
Carfilzomib—PSMB5—cardiac atrium—thymus cancer	0.0194	0.0328	CbGeAlD
Carfilzomib—Neuritis—Octreotide—thymus cancer	0.0192	0.0965	CcSEcCtD
Carfilzomib—PSMB5—pituitary gland—thymus cancer	0.019	0.032	CbGeAlD
Carfilzomib—PSMB8—bone marrow—thymus cancer	0.0186	0.0313	CbGeAlD
Carfilzomib—PSMB8—thyroid gland—thymus cancer	0.0185	0.0313	CbGeAlD
Carfilzomib—PSMB10—lymph node—thymus cancer	0.0178	0.0301	CbGeAlD
Carfilzomib—PSMB1—cardiac atrium—thymus cancer	0.017	0.0287	CbGeAlD
Carfilzomib—PSMB8—lung—thymus cancer	0.0168	0.0284	CbGeAlD
Carfilzomib—PSMB1—pituitary gland—thymus cancer	0.0166	0.028	CbGeAlD
Carfilzomib—PSMB2—cardiac atrium—thymus cancer	0.0166	0.028	CbGeAlD
Carfilzomib—PSMB5—bone marrow—thymus cancer	0.0164	0.0277	CbGeAlD
Carfilzomib—PSMB5—thyroid gland—thymus cancer	0.0163	0.0276	CbGeAlD
Carfilzomib—PSMB2—pituitary gland—thymus cancer	0.0162	0.0273	CbGeAlD
Carfilzomib—PSMB1—lymphoid tissue—thymus cancer	0.0157	0.0266	CbGeAlD
Carfilzomib—PSMB2—lymphoid tissue—thymus cancer	0.0153	0.0259	CbGeAlD
Carfilzomib—PSMB5—lung—thymus cancer	0.0148	0.0251	CbGeAlD
Carfilzomib—PSMB1—bone marrow—thymus cancer	0.0143	0.0242	CbGeAlD
Carfilzomib—PSMB1—thyroid gland—thymus cancer	0.0143	0.0241	CbGeAlD
Carfilzomib—PSMB2—bone marrow—thymus cancer	0.014	0.0236	CbGeAlD
Carfilzomib—PSMB2—thyroid gland—thymus cancer	0.0139	0.0235	CbGeAlD
Carfilzomib—PSMB1—lung—thymus cancer	0.013	0.0219	CbGeAlD
Carfilzomib—PSMB2—lung—thymus cancer	0.0127	0.0214	CbGeAlD
Carfilzomib—PSMB8—lymph node—thymus cancer	0.0115	0.0194	CbGeAlD
Carfilzomib—Cardiac failure congestive—Octreotide—thymus cancer	0.0115	0.0577	CcSEcCtD
Carfilzomib—Pain in extremity—Octreotide—thymus cancer	0.0104	0.0523	CcSEcCtD
Carfilzomib—PSMB5—lymph node—thymus cancer	0.0102	0.0172	CbGeAlD
Carfilzomib—PSMB1—lymph node—thymus cancer	0.00888	0.015	CbGeAlD
Carfilzomib—PSMB2—lymph node—thymus cancer	0.00866	0.0146	CbGeAlD
Carfilzomib—Upper respiratory tract infection—Octreotide—thymus cancer	0.00835	0.042	CcSEcCtD
Carfilzomib—Hyperglycaemia—Octreotide—thymus cancer	0.00811	0.0408	CcSEcCtD
Carfilzomib—Pneumonia—Octreotide—thymus cancer	0.00806	0.0405	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Octreotide—thymus cancer	0.00786	0.0395	CcSEcCtD
Carfilzomib—Hypoaesthesia—Octreotide—thymus cancer	0.00716	0.036	CcSEcCtD
Carfilzomib—Oedema peripheral—Octreotide—thymus cancer	0.00709	0.0356	CcSEcCtD
Carfilzomib—Cardiac disorder—Octreotide—thymus cancer	0.00668	0.0336	CcSEcCtD
Carfilzomib—Back pain—Octreotide—thymus cancer	0.00606	0.0305	CcSEcCtD
Carfilzomib—Muscle spasms—Octreotide—thymus cancer	0.00602	0.0303	CcSEcCtD
Carfilzomib—Anaemia—Octreotide—thymus cancer	0.00579	0.0291	CcSEcCtD
Carfilzomib—Cough—Octreotide—thymus cancer	0.00546	0.0275	CcSEcCtD
Carfilzomib—Hypertension—Octreotide—thymus cancer	0.00541	0.0272	CcSEcCtD
Carfilzomib—Arthralgia—Octreotide—thymus cancer	0.00533	0.0268	CcSEcCtD
Carfilzomib—Infection—Octreotide—thymus cancer	0.00508	0.0255	CcSEcCtD
Carfilzomib—Thrombocytopenia—Octreotide—thymus cancer	0.005	0.0252	CcSEcCtD
Carfilzomib—Anorexia—Octreotide—thymus cancer	0.00487	0.0245	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00466	0.0234	CcSEcCtD
Carfilzomib—Insomnia—Octreotide—thymus cancer	0.00462	0.0232	CcSEcCtD
Carfilzomib—Dyspnoea—Octreotide—thymus cancer	0.00456	0.0229	CcSEcCtD
Carfilzomib—Decreased appetite—Octreotide—thymus cancer	0.00444	0.0223	CcSEcCtD
Carfilzomib—Fatigue—Octreotide—thymus cancer	0.00441	0.0222	CcSEcCtD
Carfilzomib—Constipation—Octreotide—thymus cancer	0.00437	0.022	CcSEcCtD
Carfilzomib—Pain—Octreotide—thymus cancer	0.00437	0.022	CcSEcCtD
Carfilzomib—Body temperature increased—Octreotide—thymus cancer	0.00404	0.0203	CcSEcCtD
Carfilzomib—Asthenia—Octreotide—thymus cancer	0.00367	0.0184	CcSEcCtD
Carfilzomib—Diarrhoea—Octreotide—thymus cancer	0.0035	0.0176	CcSEcCtD
Carfilzomib—Dizziness—Octreotide—thymus cancer	0.00338	0.017	CcSEcCtD
Carfilzomib—ABCB1—hematopoietic system—thymus cancer	0.00333	0.00563	CbGeAlD
Carfilzomib—Vomiting—Octreotide—thymus cancer	0.00325	0.0163	CcSEcCtD
Carfilzomib—Headache—Octreotide—thymus cancer	0.0032	0.0161	CcSEcCtD
Carfilzomib—ABCB1—epithelium—thymus cancer	0.00304	0.00514	CbGeAlD
Carfilzomib—Nausea—Octreotide—thymus cancer	0.00304	0.0153	CcSEcCtD
Carfilzomib—ABCB1—pituitary gland—thymus cancer	0.00247	0.00417	CbGeAlD
Carfilzomib—ABCB1—lymphoid tissue—thymus cancer	0.00234	0.00396	CbGeAlD
Carfilzomib—ABCB1—bone marrow—thymus cancer	0.00214	0.00361	CbGeAlD
Carfilzomib—ABCB1—thyroid gland—thymus cancer	0.00213	0.0036	CbGeAlD
Carfilzomib—ABCB1—lung—thymus cancer	0.00193	0.00327	CbGeAlD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	0.00147	0.00704	CbGpPWpGaD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	0.00147	0.00704	CbGpPWpGaD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	0.00145	0.00694	CbGpPWpGaD
Carfilzomib—PSMB2—Mitotic G1-G1/S phases—CDKN2A—thymus cancer	0.00142	0.00678	CbGpPWpGaD
Carfilzomib—PSMB5—Mitotic G1-G1/S phases—CDKN2A—thymus cancer	0.00142	0.00678	CbGpPWpGaD
Carfilzomib—PSMB1—Mitotic G1-G1/S phases—CDKN2A—thymus cancer	0.00142	0.00678	CbGpPWpGaD
Carfilzomib—PSMB1—Host Interactions of HIV factors—CD4—thymus cancer	0.00141	0.00675	CbGpPWpGaD
Carfilzomib—PSMB5—Host Interactions of HIV factors—CD4—thymus cancer	0.00141	0.00675	CbGpPWpGaD
Carfilzomib—PSMB2—Host Interactions of HIV factors—CD4—thymus cancer	0.00141	0.00675	CbGpPWpGaD
Carfilzomib—PSMB8—Mitotic G1-G1/S phases—CDKN2A—thymus cancer	0.0014	0.00668	CbGpPWpGaD
Carfilzomib—PSMB8—Host Interactions of HIV factors—CD4—thymus cancer	0.00139	0.00665	CbGpPWpGaD
Carfilzomib—ABCB1—lymph node—thymus cancer	0.00132	0.00223	CbGeAlD
Carfilzomib—PSMB1—B Cell Activation—KIT—thymus cancer	0.0013	0.00622	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—KIT—thymus cancer	0.0013	0.00622	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—KIT—thymus cancer	0.0013	0.00622	CbGpPWpGaD
Carfilzomib—PSMB8—B Cell Activation—KIT—thymus cancer	0.00128	0.00613	CbGpPWpGaD
Carfilzomib—PSMB10—Regulation of mRNA stability by proteins that bind AU-rich elements—AKT1—thymus cancer	0.00126	0.00603	CbGpPWpGaD
Carfilzomib—PSMB9—Regulation of mRNA stability by proteins that bind AU-rich elements—AKT1—thymus cancer	0.00125	0.006	CbGpPWpGaD
Carfilzomib—PSMB10—HIV Infection—CD4—thymus cancer	0.00121	0.00578	CbGpPWpGaD
Carfilzomib—PSMB9—HIV Infection—CD4—thymus cancer	0.0012	0.00576	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle Checkpoints—TP53—thymus cancer	0.00117	0.00558	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle Checkpoints—TP53—thymus cancer	0.00116	0.00555	CbGpPWpGaD
Carfilzomib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—thymus cancer	0.00115	0.00552	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CYLD—thymus cancer	0.00114	0.00547	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CYLD—thymus cancer	0.00114	0.00545	CbGpPWpGaD
Carfilzomib—PSMB1—Regulation of mRNA stability by proteins that bind AU-rich elements—AKT1—thymus cancer	0.000955	0.00457	CbGpPWpGaD
Carfilzomib—PSMB5—Regulation of mRNA stability by proteins that bind AU-rich elements—AKT1—thymus cancer	0.000955	0.00457	CbGpPWpGaD
Carfilzomib—PSMB2—Regulation of mRNA stability by proteins that bind AU-rich elements—AKT1—thymus cancer	0.000955	0.00457	CbGpPWpGaD
Carfilzomib—PSMB8—Regulation of mRNA stability by proteins that bind AU-rich elements—AKT1—thymus cancer	0.000941	0.0045	CbGpPWpGaD
Carfilzomib—PSMB10—Apoptosis—TP53—thymus cancer	0.000931	0.00446	CbGpPWpGaD
Carfilzomib—PSMB9—Apoptosis—TP53—thymus cancer	0.000927	0.00443	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CD8A—thymus cancer	0.000921	0.00441	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CD8A—thymus cancer	0.000917	0.00438	CbGpPWpGaD
Carfilzomib—PSMB1—HIV Infection—CD4—thymus cancer	0.000916	0.00438	CbGpPWpGaD
Carfilzomib—PSMB5—HIV Infection—CD4—thymus cancer	0.000916	0.00438	CbGpPWpGaD
Carfilzomib—PSMB2—HIV Infection—CD4—thymus cancer	0.000916	0.00438	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—MAML2—thymus cancer	0.000904	0.00432	CbGpPWpGaD
Carfilzomib—PSMB8—HIV Infection—CD4—thymus cancer	0.000903	0.00432	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—MAML2—thymus cancer	0.000899	0.0043	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle Checkpoints—TP53—thymus cancer	0.000884	0.00423	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle Checkpoints—TP53—thymus cancer	0.000884	0.00423	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle Checkpoints—TP53—thymus cancer	0.000884	0.00423	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle Checkpoints—TP53—thymus cancer	0.000872	0.00417	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CYLD—thymus cancer	0.000867	0.00415	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CYLD—thymus cancer	0.000867	0.00415	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CYLD—thymus cancer	0.000867	0.00415	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CYLD—thymus cancer	0.000855	0.00409	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MAML2—thymus cancer	0.000839	0.00401	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MAML2—thymus cancer	0.000835	0.00399	CbGpPWpGaD
Carfilzomib—PSMB10—Apoptosis—AKT1—thymus cancer	0.000787	0.00376	CbGpPWpGaD
Carfilzomib—PSMB9—Apoptosis—AKT1—thymus cancer	0.000783	0.00374	CbGpPWpGaD
Carfilzomib—PSMB10—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.000741	0.00354	CbGpPWpGaD
Carfilzomib—PSMB9—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.000737	0.00353	CbGpPWpGaD
Carfilzomib—PSMB2—Apoptosis—TP53—thymus cancer	0.000706	0.00338	CbGpPWpGaD
Carfilzomib—PSMB5—Apoptosis—TP53—thymus cancer	0.000706	0.00338	CbGpPWpGaD
Carfilzomib—PSMB1—Apoptosis—TP53—thymus cancer	0.000706	0.00338	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD8A—thymus cancer	0.000698	0.00334	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD8A—thymus cancer	0.000698	0.00334	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD8A—thymus cancer	0.000698	0.00334	CbGpPWpGaD
Carfilzomib—PSMB8—Apoptosis—TP53—thymus cancer	0.000696	0.00333	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—KIT—thymus cancer	0.000692	0.00331	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—KIT—thymus cancer	0.000688	0.00329	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD8A—thymus cancer	0.000688	0.00329	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle, Mitotic—CDKN2A—thymus cancer	0.000686	0.00328	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MAML2—thymus cancer	0.000685	0.00328	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MAML2—thymus cancer	0.000685	0.00328	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MAML2—thymus cancer	0.000685	0.00328	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle, Mitotic—CDKN2A—thymus cancer	0.000682	0.00326	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL2—thymus cancer	0.000675	0.00323	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MAML2—thymus cancer	0.000675	0.00323	CbGpPWpGaD
Carfilzomib—PSMB10—B Cell Activation—AKT1—thymus cancer	0.000655	0.00313	CbGpPWpGaD
Carfilzomib—PSMB9—B Cell Activation—AKT1—thymus cancer	0.000651	0.00312	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAML2—thymus cancer	0.000636	0.00304	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAML2—thymus cancer	0.000636	0.00304	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAML2—thymus cancer	0.000636	0.00304	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAML2—thymus cancer	0.000627	0.003	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—CDKN2A—thymus cancer	0.000613	0.00293	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—CDKN2A—thymus cancer	0.00061	0.00292	CbGpPWpGaD
Carfilzomib—PSMB10—TCF dependent signaling in response to WNT—AKT1—thymus cancer	0.000599	0.00286	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism of mRNA—AKT1—thymus cancer	0.000597	0.00285	CbGpPWpGaD
Carfilzomib—PSMB2—Apoptosis—AKT1—thymus cancer	0.000596	0.00285	CbGpPWpGaD
Carfilzomib—PSMB1—Apoptosis—AKT1—thymus cancer	0.000596	0.00285	CbGpPWpGaD
Carfilzomib—PSMB5—Apoptosis—AKT1—thymus cancer	0.000596	0.00285	CbGpPWpGaD
Carfilzomib—PSMB9—TCF dependent signaling in response to WNT—AKT1—thymus cancer	0.000596	0.00285	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism of mRNA—AKT1—thymus cancer	0.000594	0.00284	CbGpPWpGaD
Carfilzomib—PSMB8—Apoptosis—AKT1—thymus cancer	0.000588	0.00281	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAML2—thymus cancer	0.000587	0.00281	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAML2—thymus cancer	0.000585	0.0028	CbGpPWpGaD
Carfilzomib—PSMB10—RNF mutants show enhanced WNT signaling and proliferation—AKT1—thymus cancer	0.00058	0.00277	CbGpPWpGaD
Carfilzomib—PSMB9—RNF mutants show enhanced WNT signaling and proliferation—AKT1—thymus cancer	0.000577	0.00276	CbGpPWpGaD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.000562	0.00269	CbGpPWpGaD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.000562	0.00269	CbGpPWpGaD
Carfilzomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.000562	0.00269	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD8A—thymus cancer	0.000559	0.00267	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD8A—thymus cancer	0.000556	0.00266	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—IL2—thymus cancer	0.000555	0.00265	CbGpPWpGaD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.000554	0.00265	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling by WNT in cancer—AKT1—thymus cancer	0.000538	0.00257	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling by WNT in cancer—AKT1—thymus cancer	0.000536	0.00256	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CD4—thymus cancer	0.000529	0.00253	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CD4—thymus cancer	0.000526	0.00252	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—KIT—thymus cancer	0.000524	0.00251	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—KIT—thymus cancer	0.000524	0.00251	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—KIT—thymus cancer	0.000524	0.00251	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—CDKN2A—thymus cancer	0.00052	0.00249	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—CDKN2A—thymus cancer	0.00052	0.00249	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—CDKN2A—thymus cancer	0.00052	0.00249	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—KIT—thymus cancer	0.000517	0.00247	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—CDKN2A—thymus cancer	0.000512	0.00245	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism of RNA—AKT1—thymus cancer	0.000511	0.00244	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism of RNA—AKT1—thymus cancer	0.000508	0.00243	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—AKT1—thymus cancer	0.000496	0.00237	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—AKT1—thymus cancer	0.000496	0.00237	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—AKT1—thymus cancer	0.000496	0.00237	CbGpPWpGaD
Carfilzomib—PSMB8—B Cell Activation—AKT1—thymus cancer	0.000489	0.00234	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—CDKN2A—thymus cancer	0.000465	0.00222	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—CDKN2A—thymus cancer	0.000465	0.00222	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—CDKN2A—thymus cancer	0.000465	0.00222	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—CDKN2A—thymus cancer	0.000458	0.00219	CbGpPWpGaD
Carfilzomib—PSMB5—TCF dependent signaling in response to WNT—AKT1—thymus cancer	0.000454	0.00217	CbGpPWpGaD
Carfilzomib—PSMB1—TCF dependent signaling in response to WNT—AKT1—thymus cancer	0.000454	0.00217	CbGpPWpGaD
Carfilzomib—PSMB2—TCF dependent signaling in response to WNT—AKT1—thymus cancer	0.000454	0.00217	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism of mRNA—AKT1—thymus cancer	0.000452	0.00216	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism of mRNA—AKT1—thymus cancer	0.000452	0.00216	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism of mRNA—AKT1—thymus cancer	0.000452	0.00216	CbGpPWpGaD
Carfilzomib—PSMB8—TCF dependent signaling in response to WNT—AKT1—thymus cancer	0.000447	0.00214	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism of mRNA—AKT1—thymus cancer	0.000446	0.00213	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAML2—thymus cancer	0.000445	0.00213	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAML2—thymus cancer	0.000445	0.00213	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAML2—thymus cancer	0.000445	0.00213	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling by Wnt—AKT1—thymus cancer	0.000444	0.00212	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling by Wnt—AKT1—thymus cancer	0.000442	0.00211	CbGpPWpGaD
Carfilzomib—PSMB5—RNF mutants show enhanced WNT signaling and proliferation—AKT1—thymus cancer	0.000439	0.0021	CbGpPWpGaD
Carfilzomib—PSMB1—RNF mutants show enhanced WNT signaling and proliferation—AKT1—thymus cancer	0.000439	0.0021	CbGpPWpGaD
Carfilzomib—PSMB2—RNF mutants show enhanced WNT signaling and proliferation—AKT1—thymus cancer	0.000439	0.0021	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAML2—thymus cancer	0.000439	0.0021	CbGpPWpGaD
Carfilzomib—PSMB8—RNF mutants show enhanced WNT signaling and proliferation—AKT1—thymus cancer	0.000433	0.00207	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD8A—thymus cancer	0.000423	0.00202	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD8A—thymus cancer	0.000423	0.00202	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD8A—thymus cancer	0.000423	0.00202	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KIT—thymus cancer	0.000419	0.00201	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KIT—thymus cancer	0.000417	0.002	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD8A—thymus cancer	0.000417	0.002	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling by WNT in cancer—AKT1—thymus cancer	0.000408	0.00195	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling by WNT in cancer—AKT1—thymus cancer	0.000408	0.00195	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling by WNT in cancer—AKT1—thymus cancer	0.000408	0.00195	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling by WNT in cancer—AKT1—thymus cancer	0.000402	0.00192	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD4—thymus cancer	0.000401	0.00192	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD4—thymus cancer	0.000401	0.00192	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD4—thymus cancer	0.000401	0.00192	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD4—thymus cancer	0.000395	0.00189	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KIT—thymus cancer	0.000387	0.00185	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism of RNA—AKT1—thymus cancer	0.000387	0.00185	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism of RNA—AKT1—thymus cancer	0.000387	0.00185	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism of RNA—AKT1—thymus cancer	0.000387	0.00185	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KIT—thymus cancer	0.000385	0.00184	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism of RNA—AKT1—thymus cancer	0.000382	0.00182	CbGpPWpGaD
Carfilzomib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thymus cancer	0.000347	0.00166	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TP53—thymus cancer	0.000341	0.00163	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TP53—thymus cancer	0.00034	0.00162	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling by Wnt—AKT1—thymus cancer	0.000336	0.00161	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling by Wnt—AKT1—thymus cancer	0.000336	0.00161	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling by Wnt—AKT1—thymus cancer	0.000336	0.00161	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling by Wnt—AKT1—thymus cancer	0.000332	0.00159	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD4—thymus cancer	0.000321	0.00153	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD4—thymus cancer	0.000319	0.00153	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KIT—thymus cancer	0.000318	0.00152	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KIT—thymus cancer	0.000318	0.00152	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KIT—thymus cancer	0.000318	0.00152	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KIT—thymus cancer	0.000313	0.0015	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—CD4—thymus cancer	0.000296	0.00142	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL2—thymus cancer	0.000295	0.00141	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—CD4—thymus cancer	0.000295	0.00141	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL2—thymus cancer	0.000294	0.00141	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KIT—thymus cancer	0.000294	0.0014	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KIT—thymus cancer	0.000294	0.0014	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KIT—thymus cancer	0.000294	0.0014	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KIT—thymus cancer	0.000289	0.00138	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KIT—thymus cancer	0.000271	0.0013	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KIT—thymus cancer	0.00027	0.00129	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—AKT1—thymus cancer	0.000264	0.00126	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—AKT1—thymus cancer	0.000263	0.00126	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—thymus cancer	0.000259	0.00124	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—thymus cancer	0.000259	0.00124	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—thymus cancer	0.000259	0.00124	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—thymus cancer	0.000255	0.00122	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD4—thymus cancer	0.000243	0.00116	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD4—thymus cancer	0.000243	0.00116	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD4—thymus cancer	0.000243	0.00116	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD4—thymus cancer	0.00024	0.00115	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CD4—thymus cancer	0.000224	0.00107	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CD4—thymus cancer	0.000224	0.00107	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CD4—thymus cancer	0.000224	0.00107	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL2—thymus cancer	0.000224	0.00107	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL2—thymus cancer	0.000224	0.00107	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL2—thymus cancer	0.000224	0.00107	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CD4—thymus cancer	0.000221	0.00106	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL2—thymus cancer	0.000221	0.00106	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KIT—thymus cancer	0.000206	0.000983	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KIT—thymus cancer	0.000206	0.000983	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KIT—thymus cancer	0.000206	0.000983	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KIT—thymus cancer	0.000203	0.000969	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—AKT1—thymus cancer	0.0002	0.000957	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—AKT1—thymus cancer	0.0002	0.000957	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—AKT1—thymus cancer	0.0002	0.000957	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—AKT1—thymus cancer	0.000197	0.000943	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL2—thymus cancer	0.000191	0.000913	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL2—thymus cancer	0.00019	0.000909	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	0.000176	0.000841	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—thymus cancer	0.00016	0.000766	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—thymus cancer	0.000159	0.000762	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—thymus cancer	0.000159	0.000761	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—thymus cancer	0.000158	0.000758	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	0.000148	0.00071	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—thymus cancer	0.000148	0.000707	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—thymus cancer	0.000147	0.000704	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—thymus cancer	0.000145	0.000692	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—thymus cancer	0.000145	0.000692	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—thymus cancer	0.000145	0.000692	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—thymus cancer	0.000143	0.000682	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—thymus cancer	0.000124	0.000592	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—thymus cancer	0.000123	0.000589	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—thymus cancer	0.000123	0.000586	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—thymus cancer	0.000122	0.000583	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—thymus cancer	0.000121	0.00058	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—thymus cancer	0.000121	0.00058	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—thymus cancer	0.000121	0.00058	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—thymus cancer	0.000121	0.000577	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—thymus cancer	0.000121	0.000577	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—thymus cancer	0.000121	0.000577	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—thymus cancer	0.00012	0.000572	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—thymus cancer	0.000119	0.000569	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—thymus cancer	0.000112	0.000536	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—thymus cancer	0.000112	0.000536	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—thymus cancer	0.000112	0.000536	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—thymus cancer	0.00011	0.000528	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—thymus cancer	0.000103	0.000495	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—thymus cancer	0.000103	0.000493	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—thymus cancer	9.38e-05	0.000449	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—thymus cancer	9.38e-05	0.000449	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—thymus cancer	9.38e-05	0.000449	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—thymus cancer	9.29e-05	0.000444	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—thymus cancer	9.29e-05	0.000444	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—thymus cancer	9.29e-05	0.000444	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—thymus cancer	9.25e-05	0.000442	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—thymus cancer	9.16e-05	0.000438	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—thymus cancer	7.84e-05	0.000375	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—thymus cancer	7.84e-05	0.000375	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—thymus cancer	7.84e-05	0.000375	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—thymus cancer	7.73e-05	0.00037	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—thymus cancer	2.76e-05	0.000132	CbGpPWpGaD
